Tesaro On Track For Mid-Year NDA Filing Of Oral CINV Candidate Rolapitant
This article was originally published in Pharmaceutical Approvals Monthly
While awaiting data from the third and final Phase III trial of the oral cancer supportive care candidate, Tesaro also will advance an I.V. formulation of rolapitant. Meanwhile, PARP inhibitor niraparib is in two Phase III trials in oncology indications, with a plan to seek other tumor types the compound might treat.